Tacalyx GmbH, a developer of antibody treatments for cancer, has appointed Jean Engela as chief executive officer. He brings extensive experience in guiding companies from research to clinical stage, as Tacalyx advances towards becoming a clinical-stage biotech. Before joining Tacalyx, Mr Engela was CEO at NBE Therapeutics where he led the company’s evolution from a start-up to a mature biotech with a diversified antibody-drug conjugate pipeline. Mr Engela was also executive drug development leader at Boehringer Ingelheim. Tacalyx’s most advanced compound, TCX-201, is in preclinical development. The company’s co-founder and former CEO, Peter Sondermann, will continue at Tacalyx as chief scientific officer.
Tacalyx announced the appointment on 2 December 2025.
Copyright 2026 Evernow Publishing Ltd.